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Abstract. Epidemiology, ventilator management, and outcome in patients receiving invasive ventilation in intensive
care units (ICUs) inmiddle-income countries are largely unknown. PRactice of VENTilation inMiddle-incomeCountries is
an international multicenter 4-week observational study of invasively ventilated adult patients in 54 ICUs from 10 Asian
countries conducted in 2017/18. Study outcomes included major ventilator settings (including tidal volume [VT] and
positive end-expiratory pressure [PEEP]); theproportionofpatients at risk for acute respiratory distress syndrome (ARDS),
according to the lung injury prediction score (LIPS), or with ARDS; the incidence of pulmonary complications; and ICU
mortality. In 1,315patients included,medianVTwassimilar in patientswith LIPS<4andpatientswith LIPS³4, but lower in
patients with ARDS (7.90 [6.8–8.9], 8.0 [6.8–9.2], and 7.0 [5.8–8.4] mL/kg Predicted body weight; P = 0.0001). Median
PEEPwassimilar in patientswith LIPS<4andLIPS³4, but higher in patientswithARDS (five [5–7], five [5–8], and10 [5–12]
cmH2O; P < 0.0001). The proportions of patients with LIPS ³ 4 or with ARDSwere 68% (95%CI: 66–71) and 7% (95%CI:
6–8), respectively. Pulmonary complications increased stepwise from patients with LIPS < 4 to patients with LIPS ³ 4 and
patients with ARDS (19%, 21%, and 38% respectively; P = 0.0002), with a similar trend in ICUmortality (17%, 34%, and
45% respectively; P < 0.0001). The capacity of the LIPS to predict development of ARDS was poor (receiver operating
characteristic [ROC] area under the curve [AUC] of 0.62, 95% CI: 0.54–0.70). In Asian middle-income countries, where
two-thirds of ventilated patients are at risk for ARDS according to the LIPS and pulmonary complications are frequent,
setting of VT is globally in line with current recommendations.
INTRODUCTION
Although invasive ventilation is an essential part of critical
care and can be a life-saving intervention, it also has strong
potential to cause or worsen lung injury.1 The risk of the so-
called ventilator-induced lung injury can be substantially re-
duced by applying lung-protective ventilation including a low
tidal volume (VT) and a sufficient positive end-expiratory
pressure (PEEP). Two recent worldwide observational studies
suggest improvements in ventilator management over recent
decades, such as lower VT and higher PEEP, confirming
trends observed in earlier service reviews.2–6 The recent
“PRactice of VENTilation (PRoVENT) in critically ill patients
without acute respiratory distress syndrome (ARDS)” study7
and the “Large observational study to UNderstand the Global
impact of Severe Acute respiratory Failure” (LUNG SAFE)8
showed more than half of patients receiving protective
ventilation.
Evidence for benefit and implementation of protective
ventilation is mostly from high-income countries.2–4,7–9 It is
uncertain to what extent protective ventilation is being prac-
ticed in middle-income countries, where intensive care units
(ICUs) and thus invasive ventilation are increasingly becoming
available. Participation of Asian middle-income country ICUs
in recent multinational ventilation studies has been scant.4,7
Few subnational studies explored the practice of ventilation
showing variable adoption of protective ventilation.5,10 This
limitation may lead to a deficient insight on actual use of
protective ventilation in resource-limited ICUs. Significant
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differences with regard to practice of care affect resource-
limited settings that go beyond the context-specific patient
casemix.10Challenges todeliver high-quality ventilation involve
equipment itself, as inaccurate flowmeters or malfunctioning
sensors hinder ventilator’s reliability. Further challenges derive
from monitoring, including continuous pulse oximetry, cap-
nography, repeated blood gas analysis, and blood pressure
measurements, as well as human resources and a proper
infrastructure.11,12 These challenges may make invasive venti-
lation less safe and may hamper implementation of protective
ventilation.
The current study aimed to describe current practices of
invasive ventilation in ICUs in Asian middle-income countries
as well as the epidemiological characteristics and disease
outcome of patients receiving invasive ventilation. We per-
formed an international multicenter prospective 4-week co-
hort study and describe associations between ventilator
settings and patient-centered outcomes. We hypothesized
that ventilation practices do not routinely include lung-
protective settings like a low VT and sufficient PEEP; how-
ever, a high number of patients are at risk for or have ARDS.
METHODS
Study design and participants. PRactice of VENTilation in
Middle-income Countries is an investigator-initiated in-
ternational multicenter prospective cohort study in consecu-
tive ICU patients receiving invasive ventilation during a
predefined 4-week period. Patients were recruited in 54 ICUs
from 10 Asian countries (a complete list can be found in
Supplemental Appendix, p. 3). The study protocol has been
published previously,13 and the current report follows the
Strengthening the Reporting of Observational Studies in Epi-
demiology statement.14
Participating centers were recruited through national co-
ordinators with help from the members of PRoVENT-iMiC
steering committee. Ethics review by the Oxford Tropical
Research Ethical Committee on June 9, 2017 designated this
study asminimal risk. National and local ethics committees of
participating centers, where applicable, approved a waiver of
patient-level consent.
Patients who started invasive ventilation in the ICU during
the inclusion period were eligible for participation. However,
patients who started invasive ventilation in the emergency
room, the clinical ward, within the community or in the oper-
ating roomdirectly preceding the present ICU admissionwere
also eligible for participation, independently from the number
of hours spent under invasive ventilation in these settings.
There was no minimum time of invasive ventilation in the
participating ICU required to be included in the study. We
excluded patients younger than 18 years, patients who re-
ceived noninvasive ventilation (NIV) not followed by invasive
ventilation, patients whose invasive ventilation started before
the inclusion period of PRoVENT-iMiC, and patients transferred
from another hospital while receiving invasive ventilation.
Procedures. At the discretion of the national coordinators,
each country or region selected a recruitment period of 28
consecutive days. If possible, the period was the same for all
centers in one country or region. Site investigators were re-
sponsible for patient recruitment and follow-up until ICU dis-
charge. The study endpoint was censored at 60 days post-
admission for patients still in the ICU at this time point.
National coordinators assisted site investigators and moni-
tored the study according to GCP-guidelines, ensuring in-
tegrity and timely completion of data collection. Before the
initiation of the study, the national coordinators reviewed the
case report forms (CRFs) to evaluate clarity and consistency
(see Supplemental Appendix, pp. 24–38). A concise one-off
web-based survey on ICU structure and organizational as-
pects was performed in the participating sites, as suggested
by previous literature12 (see Supplemental Appendix, pp.
39–44).
An extended dataset was collected daily until day 7 and at
discharge from the ICU. We defined the first calendar day the
patient received invasive ventilation in the ICU as day 0, irre-
spective of ICU admission date and location of initial in-
tubation. Baseline and demographic variables were collected
on the day of admission, including data for calculation of the
Sequential Organ Failure Assessment Score (SOFA) and the
Lung Injury Prediction Score (LIPS).15 The presence of ARDS
was scored by the site investigators according to the Berlin
Definition for ARDS,16 with the option of stratifying the oxy-
genation defect according to oxygen saturation (SpO2)/
inspired fraction of oxygen (FiO2) instead of Oxygen partial
pressure (PaO2)/FiO2 cutoffs.
17–19 Thereafter, each day for the
first 3 days of ventilation, around 08:00 hours, ventilation
variables and parameters, neurological status, and basic he-
modynamic parameters were recorded. Every day until day 7,
ICU discharge, or death, the occurrence of predefined pul-
monary complications was scored. Pulmonary complications
reported in the first 24 hours of invasive ventilation were ex-
cluded from main analysis and reported separately
(Supplemental Appendix, p. 14), as may have represented the
potential reason for intubation. Site investigators also recor-
ded rescue therapies for refractory hypoxemia, including use
of neuromuscular blockers, recruitment maneuvers, and
prone positioning.
Patient data were entered into a password-secured, Internet-
based, electronic CRF (Research Electronic Data Capture,
www.projectredcap.org). Before analysis, investigators screened
all data for potentially erroneous or incomplete recordings and
verified and corrected information as appropriate.
Outcomes. The study outcomes were represented by main
ventilator settings, includingVTandPEEP; additional ventilation
variables and parameters, including oxygen fraction of inspired
air (FiO2), respiratory rate (RR),peak inspiratoryairwaypressure,
plateau, and driving pressure (Ppeak, plateau airway pressure
[Pplat], and driving pressure); the proportion of patients at risk
for or with ARDS; incidence of pulmonary complications, in-
cluding pneumonia, ARDS after start of invasive ventilation,
pneumothorax, pleural effusion, atelectasis, and cardiogenic
pulmonary edema (for definitions, see Supplemental Appendix,
p. 5); length of stay in the ICU; and all-cause ICU mortality.
Statistical analysis. The statistical analysis plan was pub-
lished before locking of the database,13 and the final version
was uploaded at clinicaltrials.gov before the end of enrolment.
Modifications from the original analysis plan are detailed in
Supplemental Appendix, p. 6. No formal sample size calcu-
lation was performed, but the predicted sample size (> 1,200
patients) based on the allocated time period and a minimum
expected enrolment rate of 20 patients/center was deemed
sufficient to provide meaningful conclusions.
Data on ventilation variables and parameters are presented
in full detail for the day of start of invasive ventilation, and for
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the successive 3 days. Predicted body weight (PBW) of male
patients was calculated as 50 + 0×91 × (height [cm] − 152.4)
and for female patients as 45.5 + 0.91 × (height [cm] − 152.4).
Driving pressurewas calculated by subtracting PEEP from the
Pplat (in volume-controlled ventilation) or maximum airway
pressure (Pmax) (in pressure-controlled ventilation). Scatter-
plots were used to present distributions of VT versus PEEP, VT
versus RR, VT versus Pplat, and VT versus driving pressure.
Cutoffs for ventilator parameters were based on widely ac-
cepted published values,7,8,20 including 8 mL/kg PBW for VT,
5 cmH2O for PEEP, 14 breaths/minute for RR, 30 cmH2O for
Pplat, and 15 cmH2O for driving pressure.
7
Patients were stratified in three groups for comparison of
the study endpoints: patients with LIPS on day 0 lower than 4
(i.e., not at risk of ARDS according to the LIPS), patients with a
LIPS of 4 or more (at risk of ARDS according to the LIPS, but
not fulfilling the criteria for ARDS), and patients with ARDS
diagnosed by the attending physician at the start of ventila-
tion. The proportion of patients with LIPS ³ 4, or with ARDS,
was calculated by dividing the number of patients with LIPS ³
4, or with ARDS, by the total number of patients. The number
of patients of patientswith LIPS³4, orwithARDS,wasderived
per ICU bed over the study period by dividing the number of
patients of patientswith LIPS³4, orwithARDS, by the number
of ICU beds available.
The number of patients developing one or more pulmonary
complications during the first 7 days following start of invasive
ventilation and patient outcomes at ICU discharge were
reported in absolute numbers and percentages. Each new
pulmonary complication was accounted for only once, con-
sidering the day of insurgence as the first day it was reported.
A competing risk analysis based on cumulative incidence
functions and “Fine and Gray” proportional sub-distribution
hazards analysis was used to model the probability of dis-
continuing mechanical ventilation in the presence of the
competing risk of death.
Univariable and multivariable analyses were performed to
identify risk factors associated with ICU mortality and devel-
opment of pulmonary complications. Covariates for the uni-
variable models were included based on clinical relevance or
the presence of imbalance at baseline. These included, but
were not limited to, ventilator settings (in particular VT and
PEEP at day 0). Covariates included in the final mixed-effect
multivariable models were identified as those with P < 0.2 in
the univariable model (including participating center as a
random effect), and not statistically associated with other in-
cluded variables. Linearity assumption was assessed plotting
the logit x thepredictor values (Supplemental Appendix, p. 23).
Thus, nonlinear variables were entered as categorical vari-
ables (according to original categories or newly categorized).
Pearson correlation coefficients were used to assess collin-
earity between predictors. Since a high level of collinearity
among Ppeak, Pplat, and driving pressure was expected, the
main model included the variable with the higher amount of
measurements between Ppeak and Pplat. Driving pressure
was considered separately in a sensitivity analysis, excluding
PEEP, Ppeak, and Pplat. Finally, the intraclass correlation
coefficient was assessed, representing the ratio of between-
site variance to total variance, ranging from 0 to 1. Multiple
imputations of missing values were not performed because of
the low number of missing values for the variables considered
(see Supplemental Appendix, p. 7). For the models exploring
ICU mortality, age and PEEP did not meet the linearity as-
sumption and were entered as categorical variables. For the
models exploring pulmonary complications, pulmonary
SOFA, PEEP, Ppeak, and LIPS did not meet the linearity as-
sumption (Supplemental Appendix, p. 23). Thus, pulmonary
SOFA was entered as a categorical variable (according to
original categories), whereas Ppeak, PEEP, and LIPS were
categorized according to clinically meaningful categories.
Sequential organ failure assessment score, FiO2, PaO2/FiO2,
and SpO2/FiO2 were excluded from the multivariable analysis
because of relationship and multicollinearity with pulmonary
SOFA. HCO3 was excluded because of multicollinearity
with pH.
In test groups of continuous normally distributed variables,
Student’s t-test and analysis of variance analysis were used.
Likewise, the Mann–Whitney U test was used in case of not
normally distributed data. Categorical variables were com-
paredwith the chi-square test or Fisher’s exact test. Statistical
uncertainty was expressed by 95% CI. To account for the
potential clusteringof observations inparticipating centers, an
additional analysis comparing ventilatory variables and out-
comes in the three study groups was performed using linear
(for numerical variables) and logistic (for categorical variables)
mixed-effects models, with center as the random effect. A P-
value of less than 0.05was considered statistically significant.
We did not correct for multiplicity across analyses; hence, the
findings should be seen as exploratory. Statistical analysis
was conducted using R (www.r-project.org, R version 3.3.1).
The study was registered at clinicaltrials.gov, NCT 03188770.
Roleof the fundingsource.External funding source for this
study was sought only in Vietnam (Wellcome Trust grants
107367/Z/15/Z and 089276/B/09/7). The first two authors and
Steering Committee members had full access to all study-
related data and had final responsibility to submit this report
for publication.
RESULTS
Study sites and patients characteristics.Of 65 ICUs in 11
countries that expressed interest in the study, 54 ICUs from10
countries took part in the study, including 1,315 patients be-
tween November 2017 andDecember 2018 (Figure 1). Patient
characteristics are shown in Table 1; ICU organizational
characteristics and available resources are detailed in
Supplemental Appendix, pp. 4–5. Three of four centers were
public government hospitals, mostly serving a mixed pop-
ulation of surgical and medical patients from both urban and
rural settings.
Risk and prevalence of ARDS. Of the included patients,
389 patients (29.6%, 95% CI: 27.1–32.1) had a LIPS < 4, 837
patients (63.7%, 95% CI: 61.1–66.3) had a LIPS ³ 4, and 89
patients (6.8%, 95% CI: 5.8–8.2) had ARDS at the start of
invasive ventilation (Table 1), and their distribution showed
substantial geographical variation (Supplemental Appendix,
p. 9). Patients with LIPS ³ 4 and patients with ARDS repre-
sented 0.88 and 0.09 cases per ICUbed over a 4-week period,
respectively. Of the patients with ARDS at study onset, 26%
hadmild ARDS, 27% hadmoderate ARDS, and the remaining
patients had severe ARDS. Of note, one of 10 patients were
ventilated for more than 12 hours in a clinical ward before
being admitted to the ICU, highlighting the issue of accessi-
bility and shortage of ICU beds in these settings.
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Ventilation management. The median and modus abso-
lute VT of 450 (400–500) mL and 500 mL resulted in a VT of 7.8
(6.8–9.1) mL/kg PBW (Table 2). Tidal volume was similar in
patients with LIPS < 4 and patients with LIPS ³ 4, but was
lower in patientswith ARDS. Tidal volumewasgreater than 8.0
mL/kg PBW in 45% of patients with LIPS < 4, in 50% of pa-
tients with LIPS ³ 4, and in 33% of patients with ARDS
(Figure 2A). A VT £ 7 mL/kg/PBW was found in one-third of
patients without ARDS, but in more than half of patients with
ARDS. The variance of VTwhen expressed inmL/kg PBWwas
large in all centers across countries (Supplemental Appendix,
p. 19). Median and mode PEEP was five (5–8) cmH2O and
5 cmH2O, respectively. Positive end-expiratory pressure was
similar in patients with LIPS < 4 and LIPS ³ 4, but was higher in
patients with ARDS (Figure 2B). Although approximately two-
thirds of patientswithout ARDSwere ventilatedwith aPEEPof
5 cmH2O or less, this happened only in one-third of patients
with ARDS. Distributions of VT against various ventilator pa-
rameters are shown in eFigure 2 (Supplemental Appendix, p.
20). Roughly 50% of patients received invasive ventilation
within the limits of what is generally accepted as lung-
protective ventilation (Supplemental Appendix, p. 20, panel A).
The lower VT used in ARDS patients was accompanied by the
use of higher set andmeasured RRs, although extreme values
(i.e. RR > 30) were seldom used (Table 2 and Supplemental
Appendix, p. 20, panel C).When the clustering of observations
in participating centers is considered, differences in VT among
the three study groups were not significant anymore (Supple-
mental Appendix, pp. 17–18).
Volume-controlled ventilation and synchronized in-
termittentmandatory ventilationwere the twomost commonly
used ventilation modes (Table 2 and Supplemental Appendix,
pp. 9–11, and 21). Pressure-controlled ventilation was used in
about one-fourth of patients, and was the most prevalent
mode in patients with ARDS. Median FiO2, RR, Ppeak, and
Pplat (Figure 2C) increased from patients with LIPS < 4 to
patients with LIPS ³ 4 and patients with ARDS. Differences in
ventilator parameters sustained during the first 3 days of in-
vasive ventilation (Figure 3). In longitudinal analysis, an in-
teraction between time and study group was found only for
FiO2 andPplat; that is, therewas a greater decrease of oxygen
supplementation in ARDS, whereas Pplat decreased only
slightly in ARDS and remained constant for the other two
groups. Median driving pressure was similar in patients with
LIPS < 4 and patients with LIPS ³ 4, but was higher in patients
with ARDS (Figure 2D).
Pulmonary complications. Overall, one-fifth of patients
developed one or more pulmonary complications during the
first 7 days of ICU stay (Table 3 and Supplemental Appendix,
pp. 12–13). Pulmonary complication rates were similar in pa-
tients with LIPS < 4 and LIPS ³ 4, but was higher in patients
with ARDS. Of all patients without ARDS at the start of venti-
lation, 51 (4%) developed ARDS during the first 7 days of ICU
stay, mostly on day 1 or 2, with no significant difference be-
tween patients with LIPS < 4 and LIPS ³ 4 (P = 0.151). The
capacity of the LIPS to predict development of ARDS was
poor (ROC AUC of 0.62, 95% CI: 0.54–0.70; Supplemental
Appendix, p. 27). Overall, 7% of patients underwent trache-
ostomy (14% in patients with ARDS), whereas 4% needed
re-intubation after an unsuccessful extubation attempt. The
frequency of tracheostomy was different among the three
groups.
Patient outcomes. When mortality in the three groups is
taken as a competing risk, at any particular time, patients with
LIPS ³ 4 were 27% less likely, and patients with ARDS were
45% less likely to be extubated than patients with LIPS < 4
(Figure 4). Almost half of patients with ARDS died in ICU,
compared with a third of patients with LIPS ³ 4 and less than a
sixth of patients with LIPS < 4. The duration of invasive ven-
tilation was longer in ARDS patients, whereas the length of
stay in ICU did not differ between the three patient groups
(Table 3). Length of stay in non-surviving patients was shorter
of roughly 1 day than that of surviving patients.
Adjunctive treatments were infrequently used, except for
muscle paralysis that was used in approximately one in every
five patients, and was about twice more frequent in patients
with ARDS. Recruitment maneuvers and prone positioning
were used infrequently and mostly in patients with ARDS.
None of the patients in this study received extracorporeal
membrane oxygenation or other extracorporeal techniques.
Univariable and multivariable analyses of factors associ-
ated with ICU mortality and pulmonary complications are lis-
ted in Table 4 and Supplemental Appendix, pp. 15–16.
According to all models and based on clinical relevance, age,
non-pulmonary SOFA, LIPS, Ppeak, heart rate, pH, and pre-
vious use of NIV before intubation were selected as potential
predictors of death in ICU.PulmonarySOFA, arterial pH levels,
andchronic liver failurewere consistently selectedaspotential
predictors of pulmonary complications.
FIGURE 1. Screening and enrolment. ARDS = acute respiratory
distress syndrome; IRB = institutional review board; LIPS = lung injury
prediction score; MV = mechanical ventilation.
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DISCUSSION
In this international, multicenter, observational study in
ICUs in Asian countries, two-thirds of patients undergoing
invasive ventilation were at risk for ARDS, according to the
LIPS,whereas only aminority of patients actually hadARDSat
the start of ventilation. Individualization of VT was applied
poorly, but applied VT levels in these limited-resource settings
were globally compatible with lung-protective ventilation. A
VT < 8 mL/kg PBW was applied in a majority of patients with
TABLE 1
Baseline patient characteristics





LIPS < 4 vs.
LIPS ³ 4 P-value*
Age (years) 57 [40, 67] 54 [37, 66] 58 [42, 68] 49 [35, 62] 0.018 0.0013
Gender, female 507/1,314 (38.6) 159 (40.9) 317/836 (37.9) 31 (34.8) 0.355 0.462
Sequential Organ Failure Assessment
score†
7 [5, 10] 6 [4, 8] 8 [6, 11] 9 [6, 12] < 0.001 < 0.0001
LIPS‡ 5 [3.5, 7] 2.5 [2, 3.5] 6 [5, 8] 7.5 [6, 8.5] < 0.001 < 0.0001
Height (cm) 163 [156, 170] 165 [158, 170] 162 [155, 170] 165 [160, 170] 0.07 0.087
Weight (kg) 64 [55, 72] 62 [55, 72] 65 [55, 73] 63 [55, 72] 0.109 0.259
Predicted body weight (kg) 58 [50.6, 66] 59 [51,66] 57 [49,66] 60 [52,66] 0.167 0.185
Body mass index (kg/m2) 23.7 [21.5, 26.9] 23.4 [21.3, 26.4] 23.9 [21.7, 27.3] 23.3 [20.8, 25.7] 0.016 0.0134
Ventilation status
Ventilation in ward before admission 144/1,314 (11.0) 43/388 (11.1) 97 (11.6) 4 (4.5) 0.871 0.125
NIV before invasive ventilation 191/1,312 (14.6) 26/388 (6.7) 124/835 (14.9) 41 (46.1) < 0.001 < 0.0001
NIV duration (minutes) 180 [36, 660] 180 [70, 960] 172 [30, 600] 220 [62, 765] 0.172 0.262
Reason for ICU admission, n (%) < 0.001 < 0.001
Planned surgery 246 (18.7) 112 (28.8) 132/836 (15.8) 2 (2.2)
Emergency surgery (excl. trauma) 145 (11.0) 31 (8.0) 107/836 (12.8) 7 (7.9)
Trauma 76 (5.8) 9 (2.3) 62/836 (7.4) 5 (5.6)
Medical condition 847 (64.5) 237 (60.9) 535/836 (64.0) 75 (84.3)
Admission source 0.036 < 0.0001
Emergency department 405/1,305 (31.0) 122/386 (31.6) 250/830 (30.1) 33 (37.1)
Operating room 340/1,305 (26.1) 118/386 (30.6) 216/830 (26.0) 6 (6.7)
Medical or surgical ward 462/1,305 (35.4) 114/386 (29.5) 303/830 (36.5) 45 (50.6)
Obstetric ward 26/1,305 (2.0) 4/386 (1.0) 20/830 (2.4) 2 (2.2)
Directly from community 7/1,305 (0.5) 4/386 (1.0) 3/830 (0.4) 0 (0.0)
Other hospital or ICU 65/1,305 (5.0) 24/386 (6.2) 38/830 (4.6) 3 (3.4)
Smoking status 0.015 0.0325
Never 665/1,314 (50.6) 211 (54.2) 401/836 (48.0) 53 (59.6)
Former 216/1,314 (16.4) 46 (11.8) 157/836 (18.8) 13 (14.6)
Current 156/1,314 (11.9) 44 (11.3) 104/836 (12.4) 8 (9.0)
Unknown 277/1,314 (21.1) 88 (22.6) 174/836 (20.8) 15 (16.9)
Reason for intubation, n (%)§
Cardiac arrest 72 (5.5) 14 (3.6) 57 (6.8) 1 (1.1) 0.035 0.0124
Anaesthesia for surgery 328 (24.9) 122 (31.4) 200 (23.9) 6 (6.7) 0.007 < 0.0001
Hemodynamic instability 186 (14.1) 33 (8.5) 132 (15.8) 21 (23.6) 0.001 < 0.0001
Other 96 (7.3) 42 (10.8) 51 (6.1) 3 (3.4) 0.005 0.0044
Depressed level of consciousness 351 (26.7) 124 (31.9) 215 (25.7) 12 (13.5) 0.029 0.0011
Acute respiratory failure 522 (39.7) 78 (20.1) 367 (43.8) 77 (86.5) < 0.001 < 0.0001
Cause of acute respiratory failure < 0.0001
Community acquired pneumonia 113/522 (21.6) 14/78 (17.9) 85/367 (23.2) 14/77 (18.2)
Nosocomial pneumonia 45/522 (8.6) 3/78 (3.8) 38/367 (10.4) 4/77 (5.2)
Unplanned postoperative ventilation 9/522 (1.7) 2/78 (2.6) 6/367 (1.6) 1/77 (1.3)
Cardiogenic pulmonary oedema 65/522 (12.5) 12/78 (15.4) 51/367 (13.9) 2/77 (2.6)
Sepsis (other than pneumonia) 98/522 (18.8) 10/78 (12.8) 79/367 (21.5) 9/77 (11.7)
COPD exacerbation 42/522 (8.0) 10/78 (12.8) 32/367 (8.7) 0/77 (0.0)
Other 112/522 (21.5) 27/78 (34.6) 76/367 (20.7) 9/77 (11.7)
Chronic comorbidities, n (%)k
None 359 (27.3) 124 (31.9) 204 (24.4) 31 (34.8) 0.007 0.0059
Arterial hypertension 533 (40.5) 150 (38.6) 357 (42.7) 26 (29.2) 0.196 0.0314
Heart failure 104 (7.9) 22 (5.7) 77 (9.2) 5 (5.6) 0.045 0.0718
Diabetes mellitus 392 (29.8) 96 (24.7) 278 (33.2) 18 (20.2) 0.003 0.0012
Chronic kidney disease 175 (13.3) 46 (11.8) 117 (14.0) 12 (13.5) 0.346 0.586
Liver cirrhosis 58 (4.4) 13 (3.3) 41 (4.9) 4 (4.5) 0.277 0.466
COPD 84 (6.4) 18 (4.6) 61 (7.3) 5 (5.6) 0.101 0.198
Cancer 118 (9.0) 31 (8.0) 79 (9.4) 8 (9.0) 0.465 0.704
Neuromuscular disease 17 (1.3) 7 (1.8) 9 (1.1) 1 (1.1) 0.442 0.573
Other 212 (16.1) 62 (15.9) 133 (15.9) 17 (19.1) 1 0.731
COPD=chronicobstructivepulmonarydisease; ICU= intensivecareunit; IQR= interquartile range; LIPS=Lung InjuryPredictionScore.Dataarenumber ofpatients/total numberof patients (%)or
median [IQR]. All parameters are measured in the first day of ventilation.
*P-value represents the comparison across the three study groups for each variable.
†Scores range from 0 to 24, with 0 the least severe.
‡Scores range from 0 to 35, with 0 the least severe.
§Nonexclusive categories.
kPatients can have more than one diagnosis.
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ARDS, and most patients without ARDS received a VT under
10 mL/kg PBW. Progression to ARDS was observed in one in
every 25 patients. Patients with ARDS received higher PEEP
than those not having ARDS. Pulmonary complications were
frequent and occur more often in patients with ARDS. Crude
ICU mortality was markedly different between patients with
LIPS < 4 versus patients with LIPS ³ 4 or with ARDS.
Considerable geographic variation was present in the pro-
portion of patients with LIPS ³ 4 for ARDS and patients with
ARDS. The disparity may be explained by differences in case
mixes attributable to factors such as admission policies,
season of enrolment, and availability of ICU beds. A cutoff of
four for the LIPS was used to define the population at risk for
developing ARDS.13 This cutoff has been used before in
several other cohorts, albeit with limited success.7,15 Using
other, higher cutoffs, unfortunately, did not improve its
accuracy.7,15 The proportion of patients with ARDS on ad-
mission reported here is similar to the preceding PRoVENT
study that was performed in high-income countries,7 but
much lower than the 22% ARDS prevalence on day 1 or 2
observed in LUNG SAFE.8 Several factors could explain this
disparity. There could be a difference in the risk for ARDS.
Another factor could be thedifference in access tomechanical
ventilation. Whereas under-recognition of ARDSmay occur in
settings studied in the current study, there may have been
over-recognition of ARDS by the computer algorithm used in
LUNG SAFE.21
The proportion of patients receiving protective ventilation
iscomparable tofindings reported in two recent investigations,7,8
challenging the hypothesis that delivering lung protective ven-
tilation is less feasible in more resource-limited settings.
These encouraging results in terms of ventilatormanagement,
and the fact that ventilator settings were not associated with
mortality or pulmonary complications, suggest other variables
should also be explored to improve outcome of ventilated
patients in resource-limited ICUs. Patients with ARDS were
more frequently receiving ventilation with protective settings.
In fact, VT in patients with ARDS in these ICUs from Asian
TABLE 2
Ventilation characteristics in the first day of mechanical ventilation





LIPS < 4 vs.
LIPS ³ 4 P-value*
Absolute VT (mL) 450 [400, 500] 450 [400, 500] 450 [400, 500] 400 [360, 470] 0.642 0.0001
Absolute VT (mL) mode 500 500 500 400 – –
VT PBW (mL/kg PBW) 7.9 [6.8, 9.1] 7.9 [6.8, 8.9] 8.0 [6.8, 9.2] 7.0 [5.8, 8.4] 0.621 0.0001
Controlled mode 7.9 [6.8, 9.1] 7.9 [6.8, 8.9] 8.0 [6.8, 9.2] 7.0 [5.8, 8.5] 0.765 0.0002
Spontaneous mode 8.1 [7.0, 9.2] 7.8 [6.5, 9.5] 8.3 [7.4, 9.3] 7.7 [7.1, 8.0] 0.372 0.4113
£ 7.0 396 (30.5) 111 (28.8) 240 (29.2) 45 (50.6) 0.0715 0.0002
7.1–8.9 561 (43.2) 181 (46.9) 350 (42.5) 30 (33.7) – –
9.0–10.0 143 (11.0) 31 (8.0) 107 (13.0) 5 (5.6) – –
> 10.0 198 (15.3) 63 (16.3) 126 (15.3) 9 (10.1) – –
VT actual body weight (mL/kg) 7.0 [6.0, 8.2] 7.1 [6.2, 8.3] 7.0 [6.0, 8.1] 6.4 [5.6, 7.3] 0.016 0.0001
Positive end-expiratory pressure (cmH2O) 5.0 [5.0, 8.0] 5.0 [5.0, 7.0] 5.0 [5.0, 7.5] 10.0 [5.0, 12.0] 0.123 < 0.0001
£ 5 804 (61.1) 261 (67.1) 520 (62.1) 23 (25.8) 0.232 < 0.0001
6–8 335 (25.5) 94 (24.2) 220 (26.3) 21 (23.6) – –
8–10 112 (8.5) 27 (6.9) 69 (8.2) 16 (18.0) – –
> 10 64 (4.9) 7 (1.8) 28 (3.3) 29 (32.6) – –
Ventilation mode, n (%) 0.0077 0.0001
Volume controlled 483 (36.7) 171 (44.0) 288 (34.4) 24 (27.0) – –
Pressure controlled 327 (24.9) 80 (20.6) 218 (26.0) 29 (32.6) – –
Pressure support ventilation 40 (3.0) 16 (4.1) 22 (2.6) 2 (2.2) – –
Synchronized intermittent mandatory
ventilation
389 (29.6) 108 (27.8) 255 (30.5) 26 (29.2) – –
Airway pressure release ventilation 3 (0.2) 0 (0.0) 1 (0.1) 2 (2.2) – –
Pressure regulated volume-controlled
ventilation
68 (5.2) 14 (3.6) 48 (5.7) 6 (6.7) – –
Other 5 (0.4) 0 (0.0) 5 (0.6) 0 (0.0) – –
Ppeak (cmH2O) 22 [18, 28] 21.0 [18, 25] 22 [18, 28] 28 [23, 36] 0.0009 < 0.0001
Pplat (cmH2O)† 18 [15, 21] 16 [14, 18] 18 [16, 21] 28 [22, 30] < 0.0001 < 0.0001
Driving pressure (cmH2O) 14 [11, 18] 13 [10, 17] 15 [11, 18] 16 [14, 20] 0.0705 0.0037
Set RR (bpm) 14 [12, 16] 14 [12, 16] 14 [14, 16] 17 [14, 22] 0.0011 < 0.0001
Measured RR (bpm) 18 [15, 22] 16 [14, 20] 18 [15, 22] 20 [16, 25] < 0.0001 < 0.0001
FiO2 (%) 50 [40, 60] 40 [40, 50] 50 [40, 60] 80 [60, 100] < 0.0001 < 0.0001
Oxygen partial pressure/FiO2 (mmHg) 258 [157, 378] 311 [229, 419] 253 [151, 375] 112 [76, 211] < 0.0001 < 0.0001
Pulse oxymetric saturation of
haemoglobin/FiO2
200 [155, 250] 245 [194, 250] 200 [150, 245] 119 [95, 167] < 0.0001 < 0.0001
Arterial pH level 7.3 [7.3, 7.4] 7.4 [7.3, 7.4] 7.3 [7.2, 7.4] 7.3 [7.2, 7.4] < 0.0001 < 0.0001
Carbon dioxide partial pressure (mmHg) 36 [31, 43] 35 [29, 40] 37 [31, 44] 41 [34, 52] 0.0020 < 0.0001
Use of neuromuscular blockers (%) 225/1,306 (17.2) 74/385 (19.2) 117/382 (14.1) 34 (38.2) 0.0267 < 0.0001
Use of prone positioning (%) 6 (0.5) 0 (0.0) 0 (0.0) 6 (6.7) – < 0.0001
Use of recruitment maneuvers (%) 24 (1.8) 0 (0.0) 8 (1.0) 16 (18.0) 0.120 < 0.0001
Tracheostomy 95 (7.2) 34 (8.7) 49 (5.9) 12 (13.5) 0.080 0.0118
Data are number of patients/total number of patients (%) or median [IQR]. FiO2 = fraction of inspired oxygen; PBW = predicted body weight; Ppeak = peak inspiratory airway pressure; Pplat =
plateau airway pressure; RR = respiratory rate; VT = tidal volume.
*P-value represents comparisons across the three study groups for each variable.
†Plateaupressure valuesare restricted topatients inwhomthis valuewas reportedand inwhomeither anassist controlmodewasusedor inwhomamodepermittingspontaneousventilationwas
used.
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middle-incomecountrieswas lower than that in those in LUNG
SAFE.8 This could suggest a better implementation of pro-
tective ventilation in these settings,5,10 but may also point to a
better titration of VT in clinically recognized ARDS. The im-
proved ventilation settings in physician-recognized ARDS
were also observed in LUNG SAFE,8 emphasizing the possi-
bility that clinical recognition can drive behavioral change.
PRactice of VENTilation inMiddle-income Countries shows
there is scant individualization in ventilation, similar to pre-
vious investigations.3,4,7 Indeed, although median and mode
VT were 450 and 500 mL, there was a large variance in VT
expressed as mL/kg PBW. The median VT in terms of mL/kg
PBWwas very similar to that in another multinational cohort,7
possibly denoting consideration for the lower average height
and thus the PBW in this population of Asian individuals. Tidal
volume based on actual body weight (ABW) was consistently
lower than the one calculated using PBW, and it is possible
several physicians still used ABW to decide on the VT to apply.
The fact thatVTdifferences amonggroupswere not significant
after accounting for clustering indicates that titration of VT in
ARDS did receive more attention in some participating cen-
ters. Despite well-contained VT, the calculated driving pres-
sure often reached suboptimal ranges associated with
increased lung injury. This parameter, however, could only be
calculated in one-third of patients, and Pmax may over-
estimate Pplat in patients under pressure-controlled ventila-
tion. These findings are important as protective ventilation
impacts survival of ICU patients.4,22–26
Most of the patients received a PEEP ³ 5 cmH2O, in
agreementwith awell-documented global upward trend in the
application of PEEP.4 Positive end-expiratory pressure did not
differ between patients with LIPS < 4 versus patients with
LIPS ³ 4, but was higher in ARDS. Higher PEEP ismostly used
in patients with ARDS, and especially in clinician-recognized
ARDS,8 as was the case of this study. The low rate of use of
recruitment maneuvers and prone positioning, mostly ob-
served in ARDS patients in this cohort, is in line with the data
reported by LUNG SAFE.8
Based on LIPS, two-thirds of patients were “at risk for
ARDS,” which is twice as high as in high-income countries.7
The proportion of patients with LIPS ³ 4who developed ARDS
during follow-up, however, was less than that reported in
previous studies in high-income settings (7–9%)7,27 and also
compared with a recent investigation focusing on the devel-
opment of ARDS in patients in Peruvian ICUs (11%).28 The
current study confirms thepoor predictive value of the LIPS for
developing ARDS7 and for pulmonary complications, how-
ever, did identify patients at increased risk of death. The higher
mortality in the group with LIPS ³ 4 may be explained, at least
in part by differences in age, Body mass index and comor-
bidities, theSOFA score on admission, and useof noninvasive
ventilation before the start of invasive ventilation. Use of
noninvasive ventilation was even independently associated
with mortality, in line with findings of previous studies in pa-
tients receiving invasive ventilation.4,29
Intensive care unit mortality was considerably lower than
that in other cohort studies from low- and middle-income
countries (LMICs),10,11,30 an improvement that mirrors global
trends.4 Thebenefit in termsofmortality reduction attributable
to a wider implementation of protective ventilation is un-
known, but possibly significant. This role is important as
protective ventilation represents an intervention relatively
FIGURE 2. Ventilation parameters at admission in patients with LIPS < 4 vs. patients with LIPS ³ 4 and those with ARDS cumulative frequency
distribution of (A) VT, (B) PEEP, (C) plateau pressure, and (D) driving pressure. Vertical dotted lines represent the cutoff for each variable, and
horizontal dotted lines represent the respective proportion of patients reaching each cutoff. Cutoffs for ventilator parameterswere like those used in
previous published reports on invasive ventilation practices, that is, 8mL/kg PBW for VT, 5 cmH2O for PEEP, 30 cmH2O for Pplat, and 15 cmH2O for
driving pressure.7 ARDS = acute respiratory distress syndrome; PBW= predicted body weight; PEEP = positive end-expiratory pressure; VT = tidal
volume. This figure appears in color at www.ajtmh.org.
1028 PISANI AND OTHERS
independent of geo-economic variations between regions
that are known to affect survival at least in ARDS.31 Intensive
care unit mortality for the ARDS group was higher than that
reported by the LUNG SAFE study,8 reflecting geo-economic
effects on patients’ outcomes.31
This study has several limitations. First, the willingness to
participate may have facilitated a selection bias toward cen-
ters with awareness concerning protective ventilation and
with more affluent resources. Second, as in any prospective
observational study, reporting and observer bias or in-
terference with daily practice cannot be excluded. Third, to
limit the investigators’ burden, granular data were limited to
the first 4 days of ventilation. This limited information re-
garding end of ventilation in a quarter of the study cohort.
Similarly, extrapulmonary complications which could have
included unknown confounders were not captured. Follow-up
was also limited to ICU discharge, limiting the available in-
formation on post-ICU patient outcomes. Also, no data were
collected on the weaning process, which will be investigated
in a separate multicenter study.32 Because of missing data, in
the competing risk regression, we could not account for
extubations due to life-sustaining therapy withdrawal caused
by medical decisions, or by economic restraints of the patient
entourage. Access to patients’ data was restricted to local
investigators and not externally monitored; thus, inclusion of
all consecutive ventilated patients was not confirmed in-
dependently. Fourth, overrepresentation of some countries
and seasonal differences could not be averted, as the number
of centers per country or the 4-week study window was not
limited by protocol. Finally, although definitions for pulmonary
complications were prepublished and provided to national
and local coordinators in localmeetings, no formal site training
was performed to homogenize complications scoring.
Strengths of this study include the wide variety of settings
and participating ICUs, increasing the generalizability of re-
sults. The prospective design assured completeness of data
collection, whereas the short time frame within which data
were collected limited the effect of practice changes during
study period. The focus on Asian LMICs allowed us to study a
large region that has thus far been underrepresented in ven-
tilation studies,4,7,8 whereas this region harbors half of the
world population.
In conclusion, PRoVENT-iMiC extends the context-specific
knowledge of ventilation practices in Asian middle-income
countries, showing alignment with other world regions with
regard to ventilation management and outcomes. However,
the study also suggests areas for quality improvement initia-
tives and subjects for clinical trials, instrumental to enhance
safety, and effectiveness of invasive ventilation in middle-
income countries.
FIGURE 3. Ventilatory parameters in the first 4 days of mechanical ventilation. Lines are means and 95%CIs. FiO2 = fraction of inspired oxygen;
PBW=predictedbodyweight;PEEP=positiveend-expiratorypressure;Ppeak=peakpressure;Pplat =plateaupressure;VT= tidal volume.P-value
is for group and time–group interaction. This figure appears in color at www.ajtmh.org.
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TABLE 3
Pulmonary complications observed in first 7 days of mechanical ventilation and clinical outcomes
All patients (n = 1,315) LIPS < 4 (n = 389) LIPS ³ 4 (n = 837) ARDS (n = 89) P-value LIPS < 4 vs. LIPS ³ 4 P-value*
Pulmonary complications, n (%)
Patients with at least one new
pulmonary complication†
283 (21.5) 72 (18.5) 177 (21.1) 34 (38.2) 0.321 0.0002
Pulmonary complication type, n (%)
Pulmonary infection 110 (8.4) 34 (8.7) 65 (7.8) 11 (12.4) 0.638 0.314
ARDS 51 (3.9) 11 (2.8) 40 (4.8) – 0.151 –
Pneumothorax 10 (0.8) 1 (0.3) 8 (1.0) 1 (1.1) 0.330 0.340
Pleural effusion 44 (3.3) 6 (1.5) 35 (4.2) 3 (3.4) 0.0263 0.057
Atelectasis 62 (4.7) 14 (3.6) 41 (4.9) 7 (7.9) 0.382 0.212
Cardiogenic pulmonary edema 28 (2.1) 6 (1.5) 20 (2.4) 2 (2.2) 0.456 0.631
New pulmonary infiltrates 72 (5.5) 21 (5.4) 40 (4.8) 11 (12.4) 0.747 0.012
Outcomes
Death in ICU 388/1,300 (29.8) 66/383 (17.2) 282/828 (34.1) 40 (44.9) < 0.0001 < 0.0001
Death during ICU stay 362/1,300 (27.8) 60/383 (15.7) 265/828 (32.0) 37 (41.6) < 0.0001 < 0.0001
Palliative care 26 (2.0) 6 (1.6) 17 (2.1) 3 (3.4) 0.726 0.540
Duration of MV (days) 2.0 [1.0, 5.0] 2.0 [1.0, 5.0] 2.0 [1.0, 5.0] 4.0 [2.0, 8.0] 0.925 0.0024
Re-intubation 52 (4.0) 16 (4.1) 34 (4.1) 2 (2.2) 1.00 0.693
Length of stay in ICU (days) 4.0 [2.0, 7.0] 3.0 [2.0, 7.0] 4.0 [2.0, 7.0] 5.0 [2.0, 9.0] 0.187 0.0641
Length of stay in survivors 4.0 [2.0, 7.0] 3.0 [2.0, 7.0] 4.0 [2.0, 7.0] 6.0 [3.0, 9.0] 0.001 0.0001
Length of stay in non-survivors 3.0 [1.0, 7.0] 3.0 [2.0, 8.0] 3.0 [1.0, 6.0] 3.0 [2.0, 8.0] 0.122 0.239
Ventilator-free days at day 28‡ 24.0 [0.0, 27.0] 26.0 [16.5, 27.0] 23.0 [0.0, 27.0] 8.0 [0.0, 24.5] < 0.0001 < 0.0001
Type of discharge for survivors
Transferred to ward 689/1,300 (53.0) 257/383 (67.1) 399/828 (48.2) 33 (37.1) < 0.0001 < 0.0001
Discharged home 46/1,300 (3.5) 11/383 (2.9) 32/828 (3.9) 3 (3.4) 0.483 0.683
Transferred to other ICU 40/1,300 (3.1) 14/383 (3.7) 25/828 (3.0) 1 (1.1) 0.683 0.454
Transferred to intermediate care 137/1,300 (10.5) 35/383 (9.1) 90/828 (10.9) 12 (13.5) 0.413 0.425
ARDS = acute respiratory distress syndrome; ICU = intensive care unit. Data are number of patients/total number of patients (%) or median [IQR].
*P-value represents comparison across the three study groups for each variable.
†Pulmonary complications diagnosed on the first 24 of invasive ventilation were excluded from analysis and reported separately.
‡ In patients who died while receiving invasive mechanical ventilation, invasive ventilation-free days are counted as 0. Patients discharged alive from ICU were assumed to be alive at day 28.
FIGURE 4. Probability of discontinuingmechanical ventilationwhen
accounting for the competing risk of death before extubation in pa-
tients with LIPS < 4 vs. patients with LIPS ³ 4 and those with ARDS
estimates is shown as hazard ratio (95% CIs). The cumulative in-
cidence function curves estimate the instantaneous probability over
timeof extubation (shown in continuous lines)whenaccounting for the
risk set attrition due to the occurrence of the competing risk (death
before extubation, shown in survival curves as dotted lines). The “Fine
and Gray” proportional sub-distribution hazards analysis was used to
model the sub-distribution hazard and deriveP-values. ARDS = acute
respiratory distress syndrome. This figure appears in color at
www.ajtmh.org.
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TABLE 4
Analysis of factors associated with intensive care unit mortality in patients receiving mechanical ventilation
Unadjusted analyses Multivariable analyses
Clinical characteristics and comorbidities Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age (years)
£ 65 1 (reference) 1 (reference)
> 65 1.37 (1.02–1.85) 0.038 1.72 (1.18–2.51) 0.005
Gender, female 1.07 (0.82–1.39) 0.628 – –
Body mass index (kg/m2) 0.99 (0.86–1.13) 0.844 – –
Hypertension 1.15 (0.88–1.50) 0.300 – –
Diabetes mellitus 1.31 (0.98–1.73) 0.064 1.04 (0.73–1.48) 0.827
Heart failure 0.74 (0.43–1.25) 0.259 – –
Chronic kidney disease 1.02 (0.49–1.46) 0.938 – –
Chronic liver failure 2.64 (1.43–4.88) 0.002 1.78 (0.84–3.79) 0.133
Chronic obstructive pulmonary disease 0.63 (0.35–1.11) 0.109 0.60 (0.30–1.20) 0.149
Cancer 1.22 (0.76–1.96) 0.406 – –
Severity of illness
SOFA total 2.14 (1.85–2.49) < 0.001 – –
Non-pulmonary SOFA 2.05 (1.78–2.38) < 0.001 1.65 (1.37–2.00) < 0.001
Pulmonary SOFA 1.31 (1.15–1.50) < 0.001 1.09 (0.89–1.33) 0.401
Lung injury prediction score 1.86 (1.61–2.15) < 0.001 1.41 (1.16–1.72) 0.001
Management
Tidal volume (mL/kg Predicted body
weight)




< 8 cmH2O 1 (reference) 1 (reference)
8–12 cmH2O 1.52 (1.02–2.26) 0.037 0.82 (0.51–1.34) 0.434
³ 12 cmH2O 2.47 (1.37–4.45) 0.002 0.72 (0.33–1.57) 0.408
Use of noninvasive ventilation before
intubation
1.53 (1.03–2.25) 0.031 1.82 (1.12–2.96) 0.015
Ventilated in ward before admission 1.47 (0.93–2.30) 0.095 1.07 (0.62–1.86) 0.803
Maximum airway pressure (cmH2O) 1.53 (1.30–1.79) < 0.001 1.26 (1.03–1.55) 0.027
Driving pressure (cmH2O) 1.43 (1.10–1.88) 0.008 – –
Respiratory rate (movements per
minute)*
1.42 (1.22–1.66) < 0.001 1.13 (0.94–1.38) 0.210
FiO2 (%) 1.74 (1.51–2.01) < 0.001 – –
Laboratory parameters
PaO2/FiO2 (mmHg)* 0.67 (0.57–0.78) < 0.001 – –
PaCO2 (mmHg) 1.10 (0.96–1.26) 0.157 0.91 (0.75–1.11) 0.342
HCO3 (mEq/L) 0.68 (0.59–0.79) < 0.001 – –
pH* 0.63 (0.53–0.73) < 0.001 0.77 (0.63–0.94) 0.001
Vital signs
SpO2 (%) 0.71 (0.61–0.83) < 0.001 – –
SpO2/FiO2 (mmHg)* 0.55 (0.47–0.64) < 0.001 – –
Heart rate (bpm)* 1.49 (1.29–1.70) < 0.001 1.27 (1.06–1.52) 0.008
Mean arterial pressure (mmHg)* 0.65 (0.56–0.75) < 0.001 0.85 (0.71–1.02) 0.080
Pulmonary complications
Occurrence of at least one
complication
1.18 (0.86–1.61) 0.311 – –
BPM = beats per minute; FiO2 = inspired fraction of oxygen; PaO2 = Oxygen partial pressure; SOFA = Sequential Organ Failure Assessment; SpO2 = oxygen saturation. All parameters were
measured in the first day of ventilation. Adjusted intraclass correlation coefficient 0.124; HCO3 was excluded from the multivariable analysis because of multicollinearity with pH. Total SOFA score
andsingle-organSOFAscoreswereexcluded from themultivariable analysis becauseofmulticollinearitywithnon-pulmonarySOFA.Drivingpressurewasexcludedbecauseofmulticollinearitywith
Pmaxandconsidered in a separateprespecifiedsensitivity analysis.PaO2/FiO2 andSpO2/FiO2 andFiO2wereexcludedbecauseof collinearitywith pulmonarySOFA.AgeandPEEPdid notmeet the
linearity assumption and were thus entered as categorical variables.
* Numerical variables were standardized in the multivariate analysis to improve convergence of the model.
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